A Versatile Complement Therapy Across Ocular, Hematologic, Renal, Dermatological, and Inflammatory Disorders. Key Highlights Commercial ...

Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the initiation of a Phase 2 basket ...

A recent study published in npj Aging reveals that epigenetic clocks, which estimate biological age by measuring DNA methylation, capture various aspects of aging biology, including immune system ...

RG-6299 targets major unmet need in IgA nephropathy with a differentiated monthly antisense therapy. Promising clinical data, global Phase III development and strong partnerships support adoption, ...

Different aging clocks showed distinct links to immune, metabolic, and cellular pathways, while new transcriptomic scores ...

Despite current therapies, many patients with lupus nephritis relapseand incur kidney damage, warranting better treatments.

NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value ...

Immune checkpoint inhibitors, cancer vaccines and cellular therapies have reshaped oncology, yet most patients still do not ...

What do "epigenetic clocks" actually measure? These lab tests have become popular tools for studying biological aging, or how ...

What do "epigenetic clocks" actually measure? These lab tests have become popular tools for studying biological aging, or how the body's cellular function changes at a faster or slower rate than ...

作为一家专注研发、生产及推广高品质药物的创新型国际化制药企业，恒瑞医药始终坚持创新与国际化战略。公司研发投入占营业收入比重连续多年保持在25%以上，位居行业前列，并以此构建起多元化且稳健的创新产品管线。截至目前，在中国获批27款1类新药、6款2类新药 ...

We are very pleased with the strong momentum and growing market acceptance in the first full quarter of YARTEMLEA’s commercial launch,” said Gregory A. Demopulos, M.D., Omeros’ Chairman and Chief ...